Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.

Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC.

Cancer Res. 2005 Aug 15;65(16):7478-84.

2.

Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC.

Semin Oncol. 2001 Dec;28(6):607-12. Review.

PMID:
11740818
3.

Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.

Potteck H, Nieuwenhuis B, Lüth A, van der Giet M, Kleuser B.

Cell Physiol Biochem. 2010;26(1):67-78. doi: 10.1159/000315107. Epub 2010 May 18. Review.

PMID:
20502006
4.

Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).

Jernberg-Wiklund H, Nilsson K.

Adv Cancer Res. 2007;97:139-65. Review.

PMID:
17419944
6.

Drug resistance in multiple myeloma: approaches to circumvention.

Dalton WS, Jove R.

Semin Oncol. 1999 Oct;26(5 Suppl 13):23-7. Review.

PMID:
10528891
7.

Drug resistance and drug development in multiple myeloma.

Dalton WS.

Semin Oncol. 2002 Dec;29(6 Suppl 17):21-5. Review.

PMID:
12520481
8.

Interleukin-6 in multiple myeloma and related plasma cell dyscrasias.

Treon SP, Anderson KC.

Curr Opin Hematol. 1998 Jan;5(1):42-8. Review.

PMID:
9515202
9.

Apoptosis and anticancer drug resistance.

Inoue S, Salah-Eldin AE, Omoteyama K.

Hum Cell. 2001 Sep;14(3):211-21. Review.

PMID:
11774740
10.

Advances in the biology of multiple myeloma: therapeutic applications.

Anderson K.

Semin Oncol. 1999 Oct;26(5 Suppl 13):10-22. Review.

PMID:
10528890
11.

Myc/max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells.

Siegel DS, Terry JA, Koury J, Barlogie B, Epstein J, Feinman R.

Curr Top Microbiol Immunol. 1997;224:257-60. Review. No abstract available.

PMID:
9308249
12.

Apoptotic signaling in multiple myeloma: therapeutic implications.

Chauhan D, Hideshima T, Anderson KC.

Int J Hematol. 2003 Aug;78(2):114-20. Review.

PMID:
12953804
13.

Cytokines and signal transduction.

Hideshima T, Podar K, Chauhan D, Anderson KC.

Best Pract Res Clin Haematol. 2005;18(4):509-24. Review.

PMID:
16026734
14.

FTY720: from bench to bedside.

Kahan BD.

Transplant Proc. 2004 Mar;36(2 Suppl):531S-543S. Review.

PMID:
15041402
15.

Novel biologically based therapeutic strategies in myeloma.

Gupta D, Hideshima T, Anderson KC.

Rev Clin Exp Hematol. 2002 Sep;6(3):301-24. Review.

PMID:
12616700
16.

Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.

Chauhan D, Anderson KC.

Apoptosis. 2003 Aug;8(4):337-43. Review.

PMID:
12815276
17.

Targeted therapy for multiple myeloma.

Anderson KC.

Semin Hematol. 2001 Jul;38(3):286-94. Review.

PMID:
11486317
18.

New insights into role of microenvironment in multiple myeloma.

Tricot GJ.

Int J Hematol. 2002 Aug;76 Suppl 1:334-6. Review.

PMID:
12430876
19.

Overview of FTY720 clinical pharmacokinetics and pharmacology.

Kovarik JM, Schmouder RL, Slade AJ.

Ther Drug Monit. 2004 Dec;26(6):585-7. Review.

PMID:
15570180
20.

Preclinical evaluation of a new immunosuppressive agent, FTY720.

Troncoso P, Kahan BD.

Clin Biochem. 1998 Jul;31(5):369-73. Review.

PMID:
9721436
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk